Latest Articles

Publication Date
All News Scientific
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance

Repare Therapeutics eyes Phase III cancer study after Mythic trial success Yahoo Finance

Published: Dec. 13, 2024, 3:28 p.m.
Read Full Article
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial CRISPR Medicine News

Published: Dec. 13, 2024, 12:56 p.m.
Read Full Article
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - BioSpace

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial BioSpace

Published: Dec. 12, 2024, 11:25 p.m.
Read Full Article
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis Seeking Alpha

Published: Dec. 12, 2024, 8:25 p.m.
Read Full Article
Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World

Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update …

Published: Dec. 4, 2024, 8:10 a.m.
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Investor Relations | Karyopharm Therapeutics

Published: Dec. 3, 2024, 12:01 p.m.
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Kilgore News Herald

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Kilgore News Herald

Published: Dec. 3, 2024, noon
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - PR Newswire

Karyopharm Therapeutics Provides Endometrial Cancer Program Update PR Newswire

Published: Dec. 3, 2024, noon
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Longview News-Journal

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Longview News-Journal

Published: Dec. 3, 2024, noon
Read Full Article
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships - Proactive Investors UK

Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships Proactive Investors UK

Published: Nov. 14, 2024, 4:39 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!